Share：
Share this content in WeChat
X
[Chinese][PDF]43723
• Review •
Application progress of whole body-magnetic resonance imaging in common tumors and screening progress in high-risk groups
LIU Huaqiong  GAO Wenxin  BA Chenghui  DI Ningning  JIANG Xingyue  XU Chang 

Cite this article as: Liu HQ, Gao WX, Ba CH, et al. Application progress of whole body-magnetic resonance imaging in common tumors and screening progress in high-risk groups[J]. Chin J Magn Reson Imaging, 2022, 13(6): 164-167. DOI:10.12015/issn.1674-8034.2022.06.035.


[Abstract] With the continuous development of society, the incidence of cancer is increasing year by year. Improving the early detection rate of lesions is helpful for clinicians to formulate effective diagnosis and treatment plans, which is of great significance to improve the survival rate and quality of life of cancer patients. Whole body-magnetic resonance imaging (WB-MRI) has great advantages in early detection of tumor lesions and screening of tumor high-risk population. WB-MRI has no ionizing radiation and high resolution of soft tissue, and it can make up for the disadvantages of high radiation dose and low soft tissue resolution in positron emission tomography/computed tomography (PET/CT), and has been verified in practical application. It can be used in early tumor lesion detection, imaging diagnosis, tumor clinical staging and therapeutic effect evaluation. At the same time, the bone destruction of metastatic bone tumor and the bone marrow infiltration of hematological tumor can be detected out. Through reviewing a large number of literatures, the author found that WB-MRI has the advantages of high accuracy and sensitivity in the detection of hematologic tumors and bone metastases as well as the screening of tumor high-risk groups. To sum up, this paper reviews the clinical application progress of WB-MRI in the detection of respiratory system tumors, digestive system tumors, hematologic tumors and bone metastases as well as the screening of tumor high-risk population.
[Keywords] whole body-magnetic resonance imaging；oncology；early lesion detection；medical imaging diagnosis；clinical staging；clinical efficacy monitoring；high-risk groups screening

LIU Huaqiong   GAO Wenxin   BA Chenghui   DI Ningning   JIANG Xingyue   XU Chang*  

Department of Radiology, Binzhou Medical University Hospital, Binzhou 256603, China

Xu C, E-mail: xuchang3183@126.com

Conflicts of interest   None.

ACKNOWLEDGMENTS Natural Science Foundation of Shandong Province (No. ZR2019BH025).
Received  2022-03-07
Accepted  2022-05-27
DOI: 10.12015/issn.1674-8034.2022.06.035
Cite this article as: Liu HQ, Gao WX, Ba CH, et al. Application progress of whole body-magnetic resonance imaging in common tumors and screening progress in high-risk groups[J]. Chin J Magn Reson Imaging, 2022, 13(6): 164-167. DOI:10.12015/issn.1674-8034.2022.06.035.

[1]
Albano D, Stecco A, Micci G, et al. Whole-body magnetic resonance imaging (WB-MRI) in oncology: an Italian survey[J]. Radiol Med, 2021, 126(2): 299-305. DOI: 10.1007/s11547-020-01242-7.
[2]
Aryal A, Kumar VS, Shamim SA, et al. What is the comparative ability of 18F-FDG PET/CT, 99mTc-MDP skeletal scintigraphy, and whole-body MRI as a staging investigation to detect skeletal metastases in patients with osteosarcoma and ewing sarcoma?[J]. Clin Orthop Relat Res, 2021, 479(8): 1768-1779. DOI: 10.1097/CORR.0000000000001681.
[3]
Albano D, Micci G, Patti C, et al. Whole-body magnetic resonance imaging: current role in patients with lymphoma[J]. Diagnostics, 2021, 11(6): 1007. DOI: 10.3390/diagnostics11061007.
[4]
Tunariu N, Blackledge M, Messiou C, et al. What's new for clinical whole-body MRI (WB-MRI) in the 21st century[J]. Br J Radiol, 2020, 93(1115): 20200562. DOI: 10.1259/bjr.20200562.
[5]
Summers P, Saia G, Colombo A, et al. Whole-body magnetic resonance imaging: technique, guidelines and key applications[J]. Ecancermedicalscience, 2021, 15: 1164. DOI: 10.3332/ecancer.2021.1164.
[6]
Usuda K, Iwai S, Yamagata A, et al. Diffusion-weighted whole-body imaging with background suppression (DWIBS) is effective and economical for detection of metastasis or recurrence of lung cancer[J]. Thorac Cancer, 2021, 12(5): 676-684. DOI: 10.1111/1759-7714.13820.
[7]
Ohno Y, Takeshi Y, Takenaka D, et al. Comparison of diagnostic accuracy for TNM stage among whole-body MRI and coregistered PET/MRI using 1.5-T and 3-T MRI systems and integrated PET/CT for non-small cell lung cancer[J]. AJR Am J Roentgenol, 2020, 215(5): 1191-1198. DOI: 10.2214/AJR.19.22565.
[8]
Tomizawa M, Shinozaki F, Uchida Y, et al. Comparison of DWIBS/T2 image fusion and PET/CT for the diagnosis of cancer in the abdominal cavity[J]. Exp Ther Med, 2017, 14(4): 3754-3760. DOI: 10.3892/etm.2017.4987.
[9]
Yoon JH, Yu MH, Hur BY, et al. Detection of distant metastases in rectal cancer: contrast-enhanced CT vs whole body MRI[J]. Eur Radiol, 2021, 31(1): 104-111. DOI: 10.1007/s00330-020-07149-1.
[10]
Lee DH, Lee JM. Whole-body PET/MRI for colorectal cancer staging: is it the way forward?[J]. J Magn Reson Imaging, 2017, 45(1): 21-35. DOI: 10.1002/jmri.25337.
[11]
Sorge I, Georgi TW, Hirsch FW. Lymphomerkrankungen im kindes- und jugendalter[J]. Der Radiol, 2021, 61(7): 611-618. DOI: 10.1007/s00117-021-00873-9.
[12]
Donners R, Yiin RSZ, Koh DM, et al. Whole-body diffusion-weighted MRI in lymphoma-comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals[J]. Quant Imaging Med Surg, 2021, 11(8): 3549-3561. DOI: 10.21037/qims-21-50.
[13]
Spijkers S, Littooij AS, Kwee TC, et al. Whole-body MRI versus an FDG-PET/CT-based reference standard for staging of paediatric Hodgkin lymphoma: a prospective multicentre study[J]. Eur Radiol, 2021, 31(3): 1494-1504. DOI: 10.1007/s00330-020-07182-0.
[14]
Latifoltojar A, Duncan MKJ, Klusmann M, et al. Whole body 3.0 T magnetic resonance imaging in lymphomas: comparison of different sequence combinations for staging Hodgkin's and diffuse large B cell lymphomas[J]. J Pers Med, 2020, 10(4): E284. DOI: 10.3390/jpm10040284.
[15]
Petralia G, Padhani AR, Pricolo P, et al. Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses[J]. Radiol Med, 2019, 124(3): 218-233. DOI: 10.1007/s11547-018-0955-7.
[16]
Cerchione C, Usmani SZ, Stewart AK, et al. Gene expression profiling in multiple myeloma: redefining the paradigm of risk-adapted treatment[J]. Front Oncol, 2022, 12: 820768. DOI: 10.3389/fonc.2022.820768.
[17]
Messiou C, Porta N, Sharma B, et al. Prospective evaluation of whole-body MRI versus FDG PET/CT for lesion detection in participants with myeloma[J]. Radiol Imaging Cancer, 2021, 3(5): e210048. DOI: 10.1148/rycan.2021210048.
[18]
Mayerhoefer ME, Archibald SJ, Messiou C, et al. MRI and PET/MRI in hematologic malignancies[J]. J Magn Reson Imaging, 2020, 51(5): 1325-1335. DOI: 10.1002/jmri.26848.
[19]
Lecouvet FE, van Nieuwenhove S, Jamar F, et al. Whole-body MR imaging: the novel, "intrinsically hybrid," approach to metastases, myeloma, lymphoma, in bones and beyond[J]. PET Clin, 2018, 13(4): 505-522. DOI: 10.1016/j.cpet.2018.05.006.
[20]
Pawlyn C, Fowkes L, Otero S, et al. Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?[J]. Leukemia, 2016, 30(6): 1446-1448. DOI: 10.1038/leu.2015.338.
[21]
Stecco A, Buemi F, Iannessi A, et al. Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma[J]. Leuk Lymphoma, 2018, 59(11): 2546-2556. DOI: 10.1080/10428194.2018.1434881.
[22]
Dong HZ, Huang WY, Ji XD, et al. Prediction of early treatment response in multiple myeloma using MY-RADS total burden score, ADC, and fat fraction from whole-body MRI: impact of Anemia on predictive performance[J]. AJR Am J Roentgenol, 2022, 218(2): 310-319. DOI: 10.2214/AJR.21.26534.
[23]
Johnston EW, Latifoltojar A, Sidhu HS, et al. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging[J]. Eur Radiol, 2019, 29(6): 3159-3169. DOI: 10.1007/s00330-018-5813-4.
[24]
Nakanishi K, Tanaka J, Nakaya Y, et al. Whole-body MRI: detecting bone metastases from prostate cancer[J]. Jpn J Radiol, 2022, 40(3): 229-244. DOI: 10.1007/s11604-021-01205-6.
[25]
Stecco A, Trisoglio A, Soligo E, et al. Whole-body MRI with diffusion-weighted imaging in bone metastases: a narrative review[J]. Diagnostics (Basel), 2018, 8(3): E45. DOI: 10.3390/diagnostics8030045.
[26]
Zhang PP, Min XD, Wang L. Current status of whole-body magnetic resonance imaging in prostate cancer[J]. Chin J Magn Reson Imaging, 2021, 12(7): 121-124. DOI: 10.12015/issn.1674-8034.2021.07.029.
[27]
van Damme J, Tombal B, Collette L, et al. Comparison of 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography computed tomography (PET-CT) and whole-body magnetic resonance imaging (WB-MRI) with diffusion sequences (DWI) in the staging of advanced prostate cancer[J]. Cancers, 2021, 13(21): 5286. DOI: 10.3390/cancers13215286.
[28]
Petralia G, Padhani AR. Whole-body magnetic resonance imaging in oncology: uses and indications[J]. Magn Reson Imaging Clin N Am, 2018, 26(4): 495-507. DOI: 10.1016/j.mric.2018.06.003.
[29]
Papageorgiou I, Dvorak J, Cosma I, et al. Whole-body MRI: a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer[J]. Clin Transl Oncol, 2020, 22(8): 1321-1328. DOI: 10.1007/s12094-019-02257-x.
[30]
Buus TW, Rasmussen F, Nellemann HM, et al. Comparison of contrast-enhanced CT, dual-layer detector spectral CT, and whole-body MRI in suspected metastatic breast cancer: a prospective diagnostic accuracy study[J]. Eur Radiol, 2021, 31(12): 8838-8849. DOI: 10.1007/s00330-021-08041-2.
[31]
Lebron-Zapata L, Jochelson MS. Overview of breast cancer screening and diagnosis[J]. PET Clin, 2018, 13(3): 301-323. DOI: 10.1016/j.cpet.2018.02.001.
[32]
Petralia G, Zugni F, Summers PE, et al. Whole-body magnetic resonance imaging (WB-MRI) for cancer screening: recommendations for use[J]. Radiol Med, 2021, 126(11): 1434-1450. DOI: 10.1007/s11547-021-01392-2.
[33]
Schäfer JF, Granata C, von Kalle T, et al. Whole-body magnetic resonance imaging in pediatric oncology-recommendations by the Oncology Task Force of the ESPR[J]. Pediatr Radiol, 2020, 50(8): 1162-1174. DOI: 10.1007/s00247-020-04683-4.
[34]
Consul N, Amini B, Ibarra-Rovira JJ, et al. Li-fraumeni syndrome and whole-body MRI screening: screening guidelines, imaging features, and impact on patient management[J]. AJR Am J Roentgenol, 2021, 216(1): 252-263. DOI: 10.2214/AJR.20.23008.
[35]
Pasoglou V, Michoux N, Larbi A, et al. Whole Body MRI and oncology: recent major advances[J]. Br J Radiol, 2018, 91(1090): 20170664. DOI: 10.1259/bjr.20170664.
[36]
Basar Y, Alis D, Tekcan Sanli DE, et al. Whole-body MRI for preventive health screening: management strategies and clinical implications[J]. Eur J Radiol, 2021, 137: 109584. DOI: 10.1016/j.ejrad.2021.109584.
[37]
Zugni F, Padhani AR, Koh DM, et al. Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations[J]. Cancer Imaging, 2020, 20(1): 34. DOI: 10.1186/s40644-020-00315-0.

PREV Development of artificial intelligence in diagnosis and treatment of spinal diseases
NEXT Application progress of imaging technology in high-pressure injection injury
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn